{"product_id":"nanoparticles-in-gynecologic-cancers-a-20-year-research-review-made-simple","title":"Nanoparticles in Gynecologic Cancers: A 20-Year Research Review Made Simple","description":"\u003cp\u003eGynecologic cancers — cervical, ovarian, uterine, vaginal, and vulvar cancers — remain a major threat to women's health worldwide, with 116,000+ new cases reported in 2024 alone. This study analyzed 2,843 scientific publications spanning 20 years (2004–2024) to map how nanoparticles (microscopic particles engineered for targeted drug delivery) are being used to fight these cancers. The analysis reveals explosive growth in this research field, with China publishing the most papers (1,042) and the United States exercising the greatest global influence (centrality score 0.37). Future research is trending toward silver and gold nanoparticles produced with environmentally friendly \"green synthesis\" methods, opening new possibilities for more effective and less toxic cancer treatments.\u003c\/p\u003e\n\n\u003ch1\u003eNanoparticles in Gynecologic Cancers: A 20-Year Research Review Made Simple\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#publications\"\u003eKey Finding 1: Rapid Growth in Research Output\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#countries\"\u003eKey Finding 2: Leading Countries and Institutions\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#journals\"\u003eKey Finding 3: Top Journals Publishing This Research\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#authors\"\u003eKey Finding 4: Influential Authors and Landmark Studies\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#keywords\"\u003eKey Finding 5: Research Hotspots and Future Trends\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What This Study Couldn't Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations: What Patients Should Know\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eThe review analyzed 2,843 publications from 2004 to 2024 on nanoparticles in gynecologic cancers, showing strong research growth.\u003c\/li\u003e\n\u003cli\u003eNanoparticles enable targeted drug delivery and controlled release, potentially reducing chemotherapy toxicity and improving drug effectiveness.\u003c\/li\u003e\n\u003cli\u003eEmerging research trends include silver and gold nanoparticles produced via environmentally friendly green synthesis methods.\u003c\/li\u003e\n\u003cli\u003eMost nanoparticle therapies are still in development, but some, like liposomal doxorubicin, are already FDA-approved for clinical use.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eGynecologic cancers are characterized by uncontrolled cell growth in the female reproductive organs. The five main types are cervical, ovarian, uterine, vaginal, and vulvar cancers. These malignancies pose a significant threat to women's health, affecting life expectancy, quality of life, and fertility. In 2024 alone, statistics reported over 116,000 new cases of gynecological cancers in the United States.\u003c\/p\u003e\n\n\u003cp\u003eThese cancers not only have high incidence rates but also demand urgent improvement in prognosis. The current treatment options each have important limitations:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSurgery\u003c\/strong\u003e is mainly applicable to early-stage solid tumors but carries risks of incomplete resection and potential tumor metastasis (spread) or implantation during the procedure.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChemotherapy\u003c\/strong\u003e is associated with cytotoxicity (toxicity to healthy cells) and low bioavailability, meaning the drug often doesn't reach the tumor in sufficient amounts, limiting its widespread effectiveness.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eImmunotherapy\u003c\/strong\u003e has limited clinical applicability and does not work for tumor types characterized by \"immune suppression\" or \"immune exclusion\" — situations where the immune system is blocked from attacking the cancer.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRadiotherapy\u003c\/strong\u003e remains a standard tool but can damage surrounding healthy tissue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis is where nanoparticles enter the picture. Nanoparticles are ultra-small particles (typically 1 to 100 nanometers — far thinner than a human hair) that have gained enormous attention in biomedicine. Their advantages lie in their small size, large surface area, high permeability, and ability to effectively combine with various biomaterials. These characteristics give nanoparticles significant advantages in \u003cstrong\u003edrug delivery\u003c\/strong\u003e (carrying medication directly to tumors) and \u003cstrong\u003econtrolled release\u003c\/strong\u003e (releasing the drug gradually at the right place and time).\u003c\/p\u003e\n\n\u003cp\u003eThe study gives concrete examples of how this works. In treating ovarian cancer, combining the chemotherapy drug \u003cstrong\u003epaclitaxel\u003c\/strong\u003e with other drugs in nanocarrier systems enables precise targeted delivery, reduces off-target toxicity (damage to healthy organs), and effectively improves solubility issues that have long plagued this drug. Other examples include \u003cstrong\u003esilica-coated gold nanoparticles (Au@SiO2)\u003c\/strong\u003e, which show promise in treating cervical cancer, and \u003cstrong\u003egraphene oxide nanoparticles encapsulating chlorambucil\u003c\/strong\u003e (a chemotherapy drug), which lower cellular toxicity and demonstrate high drug-loading efficiency and controlled release capabilities in treating cervical adenocarcinoma.\u003c\/p\u003e\n\n\u003cp\u003eTo make sense of this rapidly expanding field, the researchers performed a \u003cstrong\u003ebibliometric analysis\u003c\/strong\u003e — a statistical approach that tracks the evolution and structure of a research area by examining publications, citations, authors, journals, and keywords. This type of analysis has been widely used in fields such as psychiatry, obstetrics, and gynecology, but this was the first bibliometric analysis ever conducted on nanoparticles in gynecologic cancers.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThe research team searched the \u003cstrong\u003eWeb of Science Core Collection (WOSCC)\u003c\/strong\u003e database — widely recognized as a premier academic information database distinguished by its selection of high-impact journals — on June 4, 2024. They included only English-language publications categorized as either \"article\" or \"review,\" and the search period ran from \u003cstrong\u003eJanuary 1, 2004, to June 4, 2024\u003c\/strong\u003e. The starting point was chosen because very few publications existed in this field before 2004.\u003c\/p\u003e\n\n\u003cp\u003eFor data analysis and visualization, the researchers used several sophisticated software tools:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMicrosoft Excel 2021\u003c\/strong\u003e — for organizing and sorting raw data\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eR software (version 4.4.0)\u003c\/strong\u003e with the bibliometrix package — specifically designed for bibliometric analysis, used to create graphical representations of keyword counts and visual maps of research hotspot development trends\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVOSviewer (version 1.6.19.0)\u003c\/strong\u003e — used to analyze associations among countries, institutions, authors, references, and keyword co-occurrence, using probabilistic data standardization methods\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCiteSpace (version 6.1)\u003c\/strong\u003e — a robust exploration tool that employs standardized data aggregation and burst detection methods to track emerging research trends and future directions\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe researchers analyzed multiple dimensions: publication counts, country\/region collaborations, institutional networks, journal co-citation patterns, author productivity, co-cited references, and keyword frequencies. Because the data came from publicly accessible databases of published articles and involved no animal or human subjects, ethical approval from a committee was not required.\u003c\/p\u003e\n\n\u003ch2 id=\"publications\"\u003eKey Finding 1: Rapid Growth in Research Output\u003c\/h2\u003e\n\n\u003cp\u003eA total of \u003cstrong\u003e2,843 publications\u003c\/strong\u003e related to nanoparticles in gynecologic cancers were identified between January 2004 and June 2024. Of these, \u003cstrong\u003e2,661 (93.6%) were research articles\u003c\/strong\u003e and \u003cstrong\u003e182 (6.4%) were review articles\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe number of publications \u003cstrong\u003esteadily increased from 2004 to 2020\u003c\/strong\u003e. Although there was a slight decrease after 2020, the overall trend over the past 20 years has been strongly upward. From 2021 to 2023, the annual number of publications remained stable at around \u003cstrong\u003e290 per year\u003c\/strong\u003e, indicating sustained scientific attention to nanoparticles in the gynecologic cancer field.\u003c\/p\u003e\n\n\u003cp\u003eEven more striking is the explosion in citations. Citations — the number of times other researchers reference these papers — rose from just \u003cstrong\u003e4 in 2004 to 13,090 in 2023\u003c\/strong\u003e. This dramatic increase underscores the significant scientific impact and real-world relevance of this body of research.\u003c\/p\u003e\n\n\u003ch2 id=\"countries\"\u003eKey Finding 2: Leading Countries and Institutions\u003c\/h2\u003e\n\n\u003cp\u003eOver the past two decades, research on nanoparticles in gynecologic cancers has been conducted in \u003cstrong\u003e76 countries and regions\u003c\/strong\u003e. The geographic distribution shows concentrations in North America, Europe, and Asia. Here are the top 10 countries by publication count:\u003c\/p\u003e\n\n\u003ctable border=\"1\" cellpadding=\"5\" cellspacing=\"0\"\u003e\n  \u003ctr\u003e\n    \u003cth\u003eRank\u003c\/th\u003e\n    \u003cth\u003eCountry\/Region\u003c\/th\u003e\n    \u003cth\u003ePublications\u003c\/th\u003e\n    \u003cth\u003eTotal Link Strength (TLS)\u003c\/th\u003e\n    \u003cth\u003eCentrality\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003eChina\u003c\/td\u003e\n\u003ctd\u003e1,042\u003c\/td\u003e\n\u003ctd\u003e286\u003c\/td\u003e\n\u003ctd\u003e0.16\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003ctd\u003eUnited States\u003c\/td\u003e\n\u003ctd\u003e624\u003c\/td\u003e\n\u003ctd\u003e383\u003c\/td\u003e\n\u003ctd\u003e0.37\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003ctd\u003eIndia\u003c\/td\u003e\n\u003ctd\u003e399\u003c\/td\u003e\n\u003ctd\u003e216\u003c\/td\u003e\n\u003ctd\u003e0.19\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003ctd\u003eSouth Korea\u003c\/td\u003e\n\u003ctd\u003e168\u003c\/td\u003e\n\u003ctd\u003e137\u003c\/td\u003e\n\u003ctd\u003e0.05\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003ctd\u003eIran\u003c\/td\u003e\n\u003ctd\u003e157\u003c\/td\u003e\n\u003ctd\u003e96\u003c\/td\u003e\n\u003ctd\u003e0.11\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003ctd\u003eSaudi Arabia\u003c\/td\u003e\n\u003ctd\u003e113\u003c\/td\u003e\n\u003ctd\u003e164\u003c\/td\u003e\n\u003ctd\u003e0.12\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e7\u003c\/td\u003e\n\u003ctd\u003eItaly\u003c\/td\u003e\n\u003ctd\u003e87\u003c\/td\u003e\n\u003ctd\u003e81\u003c\/td\u003e\n\u003ctd\u003e0.06\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e8\u003c\/td\u003e\n\u003ctd\u003eGermany\u003c\/td\u003e\n\u003ctd\u003e67\u003c\/td\u003e\n\u003ctd\u003e85\u003c\/td\u003e\n\u003ctd\u003e0.08\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e9\u003c\/td\u003e\n\u003ctd\u003eJapan\u003c\/td\u003e\n\u003ctd\u003e61\u003c\/td\u003e\n\u003ctd\u003e74\u003c\/td\u003e\n\u003ctd\u003e0.02\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e10\u003c\/td\u003e\n\u003ctd\u003eCanada\u003c\/td\u003e\n\u003ctd\u003e61\u003c\/td\u003e\n\u003ctd\u003e41\u003c\/td\u003e\n\u003ctd\u003e0.01\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eChina leads\u003c\/strong\u003e with 1,042 publications — more than 36% of all papers in this field. It is followed by the United States (624 publications) and India (399 publications).\u003c\/p\u003e\n\n\u003cp\u003eCentrality is a measure of how pivotal a node is within a research network; scores exceeding 0.1 indicate significant global influence. Notably, despite ranking second in publication count, the \u003cstrong\u003eUnited States exhibits the highest total link strength (383) and the highest centrality (0.37)\u003c\/strong\u003e — more than double China's centrality score of 0.16. This means that while China produces the most papers, American research is more frequently connected to and influential within the international research network. India (0.19), Saudi Arabia (0.12), and Iran (0.11) also achieved centrality scores above 0.1.\u003c\/p\u003e\n\n\u003cp\u003eAt the institutional level, the \u003cstrong\u003eChinese Academy of Sciences\u003c\/strong\u003e is the clear leader, with 105 publications, the highest total link strength (102), and the highest centrality (0.17) — demonstrating its predominant influence. Other leading institutions include:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eShanghai Jiao Tong University\u003c\/strong\u003e — 55 publications, TLS 37, centrality 0.08\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUniversity of Texas MD Anderson Cancer Center\u003c\/strong\u003e — 52 publications, TLS 49, centrality 0.09\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSichuan University\u003c\/strong\u003e — 52 publications, TLS 16, centrality 0.12\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFudan University\u003c\/strong\u003e — 48 publications, TLS 33, centrality 0.02\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKing Saud University\u003c\/strong\u003e — 42 publications, TLS 13, centrality 0.13\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKonkuk University\u003c\/strong\u003e — 39 publications, TLS 27, centrality 0.13\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUniversity of Chinese Academy of Sciences\u003c\/strong\u003e — 35 publications, TLS 50, centrality 0.02\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eZhejiang University\u003c\/strong\u003e — 35 publications, TLS 9, centrality 0.03\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIslamic Azad University\u003c\/strong\u003e — 34 publications, TLS 15, centrality 0.07\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"journals\"\u003eKey Finding 3: Top Journals Publishing This Research\u003c\/h2\u003e\n\n\u003cp\u003eOver the past 20 years, \u003cstrong\u003e637 journals\u003c\/strong\u003e have published articles on nanoparticles in gynecologic cancers. Among these, 15 journals published 30 or more articles. The \u003cstrong\u003eInternational Journal of Nanomedicine\u003c\/strong\u003e leads the pack with 97 publications, followed by \u003cstrong\u003eACS Applied Materials \u0026amp; Interfaces\u003c\/strong\u003e (72 publications) and the \u003cstrong\u003eJournal of Materials Chemistry B\u003c\/strong\u003e (53 publications).\u003c\/p\u003e\n\n\u003cp\u003eThe journal with the highest impact factor among the top 15 is \u003cstrong\u003eACS Nano\u003c\/strong\u003e (impact factor 17.1), a top-tier interdisciplinary journal spanning chemistry, physics, biology, and engineering. For context, the impact factor reflects how often articles in a journal are cited in a given year — higher numbers indicate greater influence in the scientific community.\u003c\/p\u003e\n\n\u003cp\u003eThe table below shows the top 15 journals in this field:\u003c\/p\u003e\n\n\u003ctable border=\"1\" cellpadding=\"5\" cellspacing=\"0\"\u003e\n  \u003ctr\u003e\n    \u003cth\u003eRank\u003c\/th\u003e\n    \u003cth\u003eJournal Name\u003c\/th\u003e\n    \u003cth\u003ePublications\u003c\/th\u003e\n    \u003cth\u003eImpact Factor (2022)\u003c\/th\u003e\n    \u003cth\u003eJCR Quartile\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003eInternational Journal of Nanomedicine\u003c\/td\u003e\n\u003ctd\u003e97\u003c\/td\u003e\n\u003ctd\u003e8.0\u003c\/td\u003e\n\u003ctd\u003eQ2\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003ctd\u003eACS Applied Materials \u0026amp; Interfaces\u003c\/td\u003e\n\u003ctd\u003e72\u003c\/td\u003e\n\u003ctd\u003e9.5\u003c\/td\u003e\n\u003ctd\u003eQ1\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003ctd\u003eJournal of Materials Chemistry B\u003c\/td\u003e\n\u003ctd\u003e53\u003c\/td\u003e\n\u003ctd\u003e7.0\u003c\/td\u003e\n\u003ctd\u003eQ1\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003ctd\u003eJournal of Controlled Release\u003c\/td\u003e\n\u003ctd\u003e46\u003c\/td\u003e\n\u003ctd\u003e10.8\u003c\/td\u003e\n\u003ctd\u003eQ1\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003ctd\u003eRSC Advances\u003c\/td\u003e\n\u003ctd\u003e42\u003c\/td\u003e\n\u003ctd\u003e3.9\u003c\/td\u003e\n\u003ctd\u003eQ2\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003ctd\u003eInternational Journal of Molecular Sciences\u003c\/td\u003e\n\u003ctd\u003e38\u003c\/td\u003e\n\u003ctd\u003e5.6\u003c\/td\u003e\n\u003ctd\u003eQ1\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e7\u003c\/td\u003e\n\u003ctd\u003eJournal of Biomedical Nanotechnology\u003c\/td\u003e\n\u003ctd\u003e38\u003c\/td\u003e\n\u003ctd\u003e2.9\u003c\/td\u003e\n\u003ctd\u003eQ4\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e8\u003c\/td\u003e\n\u003ctd\u003eColloids and Surfaces B-Biointerfaces\u003c\/td\u003e\n\u003ctd\u003e37\u003c\/td\u003e\n\u003ctd\u003e5.8\u003c\/td\u003e\n\u003ctd\u003eQ1\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e9\u003c\/td\u003e\n\u003ctd\u003eInternational Journal of Pharmaceutics\u003c\/td\u003e\n\u003ctd\u003e37\u003c\/td\u003e\n\u003ctd\u003e5.8\u003c\/td\u003e\n\u003ctd\u003eQ1\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e10\u003c\/td\u003e\n\u003ctd\u003eNanoscale\u003c\/td\u003e\n\u003ctd\u003e37\u003c\/td\u003e\n\u003ctd\u003e6.7\u003c\/td\u003e\n\u003ctd\u003eQ1\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e11\u003c\/td\u003e\n\u003ctd\u003eBiomaterials\u003c\/td\u003e\n\u003ctd\u003e36\u003c\/td\u003e\n\u003ctd\u003e14.0\u003c\/td\u003e\n\u003ctd\u003eQ1\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003ctd\u003eScientific Reports\u003c\/td\u003e\n\u003ctd\u003e36\u003c\/td\u003e\n\u003ctd\u003e4.6\u003c\/td\u003e\n\u003ctd\u003eQ2\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e13\u003c\/td\u003e\n\u003ctd\u003eACS Nano\u003c\/td\u003e\n\u003ctd\u003e32\u003c\/td\u003e\n\u003ctd\u003e17.1\u003c\/td\u003e\n\u003ctd\u003eQ1\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e14\u003c\/td\u003e\n\u003ctd\u003eNanomaterials\u003c\/td\u003e\n\u003ctd\u003e31\u003c\/td\u003e\n\u003ctd\u003e5.3\u003c\/td\u003e\n\u003ctd\u003eQ2\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e15\u003c\/td\u003e\n\u003ctd\u003eMolecular Pharmaceutics\u003c\/td\u003e\n\u003ctd\u003e30\u003c\/td\u003e\n\u003ctd\u003e4.9\u003c\/td\u003e\n\u003ctd\u003eQ2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eAn interesting \"dual-map overlay\" analysis revealed how knowledge flows between different scientific fields. Research published in journals focusing on chemistry, materials, and physics, as well as molecular biology and genetics, is frequently cited by journals specializing in physics\/materials\/chemistry and molecular biology\/immunology. This cross-pollination of disciplines reflects the highly interdisciplinary nature of nanoparticle cancer research.\u003c\/p\u003e\n\n\u003ch2 id=\"authors\"\u003eKey Finding 4: Influential Authors and Landmark Studies\u003c\/h2\u003e\n\n\u003cp\u003eA total of \u003cstrong\u003e15,227 researchers\u003c\/strong\u003e have contributed articles to this field. The most prolific author is \u003cstrong\u003eSood, A K\u003c\/strong\u003e, who has published 30 articles, followed by \u003cstrong\u003eLopez-Berestein, G\u003c\/strong\u003e (22 articles) and \u003cstrong\u003eSteinmetz, NF\u003c\/strong\u003e (16 articles). The full top 10 author list also includes Zhang W (14), Mei L (13), Amiji MM (13), Gurunathan S (13), Chen T (13), Singh M (13), and Duan Y (12). Collaboration network mapping indicates close working relationships among many of these leading researchers.\u003c\/p\u003e\n\n\u003cp\u003eThe analysis also examined \u003cstrong\u003eco-cited authors\u003c\/strong\u003e — authors who are frequently cited together by other researchers, indicating that their work forms an intellectual foundation for the field. \u003cstrong\u003eSiegel, RL\u003c\/strong\u003e ranks first with 221 citations, followed by \u003cstrong\u003eZhang, Y\u003c\/strong\u003e (213 citations) and \u003cstrong\u003eGurunathan, S\u003c\/strong\u003e (191 citations). The top 10 co-cited authors accumulated over 1,700 citations combined, underscoring their significant influence.\u003c\/p\u003e\n\n\u003cp\u003eOne author stands out as particularly noteworthy: \u003cstrong\u003eGurunathan, S\u003c\/strong\u003e appears in both the top 10 most productive authors and the top 10 most co-cited authors. This researcher has made significant contributions to the biomedical application of nanoparticles such as graphene and silver, and has delved deeply into the biological functions of \u003cstrong\u003eexosomes\u003c\/strong\u003e — tiny cellular vesicles being explored as delivery vehicles in cancer therapy and as emerging nanoplatforms in biomedical applications.\u003c\/p\u003e\n\n\u003cp\u003eExamining the \u003cstrong\u003etop 10 most co-cited references\u003c\/strong\u003e reveals three main research themes:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCancer statistics\u003c\/strong\u003e — landmark papers from the journal \"CA: A Cancer Journal for Clinicians\" documenting global cancer burden, including the two most co-cited articles in the entire field (Cancer Statistics 2017 with 138 citations and Global Cancer Statistics 2011 with 107 citations)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNanoparticles in cancer therapy\u003c\/strong\u003e — foundational papers such as \"Nanocarriers as an emerging platform for cancer therapy\" (published in Nature Nanotechnology, 2007, 91 citations) and \"Nanoparticle therapeutics: an emerging treatment modality for cancer\" (Nature Reviews Drug Discovery, 2008, 49 citations)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCancer treatment methods and mechanisms\u003c\/strong\u003e — including the landmark NEJM study on intraperitoneal cisplatin and paclitaxel in ovarian cancer (2006, 45 citations) and research on gold nanoparticle uptake into mammalian cells (Nano Letters, 2006, 44 citations)\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe co-citation network of references (those cited 20 or more times) forms five distinct clusters, each representing a research front:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCluster 1 (red):\u003c\/strong\u003e Nanotechnology applications in cancer therapy — the largest contributor to cited volume\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCluster 2 (green):\u003c\/strong\u003e Mechanisms of nanoparticle action at the cellular level\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCluster 3 (blue):\u003c\/strong\u003e Tumor data statistics — also a major contributor to cited volume\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCluster 4 (yellow):\u003c\/strong\u003e Drug delivery systems\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCluster 5 (purple):\u003c\/strong\u003e Challenges in clinical applications of nanomedicine\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe study also identified the \u003cstrong\u003etop 25 references with the strongest \"citation bursts\"\u003c\/strong\u003e — papers that experienced sudden surges in citations, signaling emerging research fronts. Among these, 12 articles have experienced recent bursts that may indicate future trends. Five focus on cancer data statistics, four provide comprehensive reviews of ovarian and cervical cancers (the two most prominent gynecologic malignancies), and three concentrate on cutting-edge therapeutic approaches.\u003c\/p\u003e\n\n\u003ch2 id=\"keywords\"\u003eKey Finding 5: Research Hotspots and Future Trends\u003c\/h2\u003e\n\n\u003cp\u003eKeyword analysis provides a window into what researchers are actually studying. The top 10 most frequently occurring keywords in this field are:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNanoparticles\u003c\/strong\u003e — 518 occurrences\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDrug delivery\u003c\/strong\u003e — 396 occurrences\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDelivery\u003c\/strong\u003e — 382 occurrences\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIn-vitro\u003c\/strong\u003e (studies done in test tubes\/laboratory dishes) — 319 occurrences\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCells\u003c\/strong\u003e — 278 occurrences\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTherapy\u003c\/strong\u003e — 247 occurrences\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCancer\u003c\/strong\u003e — 246 occurrences\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eApoptosis\u003c\/strong\u003e (programmed cell death, the goal of cancer treatment) — 215 occurrences\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExpression\u003c\/strong\u003e (gene\/protein expression) — 190 occurrences\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRelease\u003c\/strong\u003e (drug release) — 167 occurrences\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe keyword co-occurrence map includes \u003cstrong\u003e484 nodes and 25,920 links\u003c\/strong\u003e, organized into four major clusters:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRed cluster:\u003c\/strong\u003e Common gynecologic malignancies and treatment modalities\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGreen cluster:\u003c\/strong\u003e Commonly used nanoparticles in gynecologic malignancies\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBlue cluster:\u003c\/strong\u003e Drug delivery systems\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eYellow cluster:\u003c\/strong\u003e Clinical mechanisms of nanoparticle action at the cellular level\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMost importantly, the analysis of keyword trends over time reveals where the field is heading. Keywords closer to yellow in the overlay visualization indicate recent significant impact. Three keywords stand out as emerging hotspots: \u003cstrong\u003e\"silver nanoparticles,\" \"green synthesis,\"\u003c\/strong\u003e and \u003cstrong\u003e\"antibacterial.\"\u003c\/strong\u003e This suggests that future research will likely focus on optimizing synthesis techniques — particularly environmentally friendly \"green\" methods for producing silver and gold nanoparticles — and advancing preclinical studies toward actual clinical applications.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eFor patients and their families, this research maps a path toward better treatments. Nanoparticles offer the potential to overcome the major limitations of conventional cancer therapies — the toxicity of chemotherapy, the invasiveness of surgery, and the limited applicability of immunotherapy.\u003c\/p\u003e\n\n\u003cp\u003eThe study highlights a critical economic dimension to these advances. The United States is a global leader in nanomedicine, accounting for \u003cstrong\u003e46% of the global market share in 2016\u003c\/strong\u003e. In 2018, the National Institutes of Health (NIH) invested an estimated \u003cstrong\u003e$445 million in nanomedicine research\u003c\/strong\u003e. This substantial financial investment has provided a solid foundation for developing nanomedicines, particularly anticancer therapies.\u003c\/p\u003e\n\n\u003cp\u003eHowever, while nanotherapy may offer a more efficient treatment option, the \u003cstrong\u003ehigh research and production costs could restrict its widespread use in resource-limited countries\u003c\/strong\u003e. This is a crucial equity concern — the benefits of nanoparticle-based treatments should not be available only to patients in wealthy nations. The authors suggest that developing countries could reduce production and supply costs through supportive policies, such as tax incentives and adjustments to patent protection. Establishing international collaboration platforms to share key technologies and research outcomes could also help lower research costs globally.\u003c\/p\u003e\n\n\u003cp\u003eFor patients, the practical takeaway is that nanoparticle-based treatments are not yet widely available in clinics, but the research foundation is being rapidly built. The sustained publication volume (~290 papers per year) and the massive jump in citations (from 4 to over 13,000 annually) indicate a fieldthat is maturing and moving closer to practical applications.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What This Study Couldn't Prove\u003c\/h2\u003e\n\n\u003cp\u003eIt is important to understand what a bibliometric analysis can and cannot tell us. This study analyzed publication patterns and citations — it did not test any nanoparticles in patients or animals. The clinical effectiveness of specific nanoparticle formulations cannot be determined from this type of research.\u003c\/p\u003e\n\n\u003cp\u003eOther limitations to keep in mind:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eThe study relied exclusively on the \u003cstrong\u003eWeb of Science Core Collection database\u003c\/strong\u003e and only included English-language \"article\" and \"review\" publications. Relevant research published in other languages or in databases not indexed in WOSCC would not be captured.\u003c\/li\u003e\n  \u003cli\u003eThe search combined terms for gynecologic cancers and nanoparticles, but some relevant papers using different terminology may have been missed.\u003c\/li\u003e\n  \u003cli\u003eThe slight decrease in publications after 2020 could reflect disruptions from the COVID-19 pandemic, shifts in research funding, or natural fluctuations — the study cannot determine the cause.\u003c\/li\u003e\n  \u003cli\u003eCitation counts can be influenced by factors unrelated to research quality, such as self-citation practices, the tendency to cite well-known authors, and \"snowball\" citation effects where papers are cited simply because they have been cited before.\u003c\/li\u003e\n  \u003cli\u003eBibliometric indicators measure academic influence, not clinical effectiveness. A highly cited paper does not necessarily mean its findings will translate into successful patient treatments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations: What Patients Should Know\u003c\/h2\u003e\n\n\u003cp\u003eFor patients currently undergoing treatment for gynecologic cancers — or supporting a loved one who is — this study offers several practical insights:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about clinical trials.\u003c\/strong\u003e Nanoparticle-based therapies are an active area of research, and some formulations are being tested in clinical trials. Ask your oncologist whether you might be eligible for a trial involving nanoparticle drug delivery systems.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand the current treatment landscape.\u003c\/strong\u003e Surgery, chemotherapy, radiotherapy, and immunotherapy remain the standard of care. Nanoparticle approaches are still largely in the research and development phase, though some nanomedicine formulations (such as liposomal doxorubicin, a nano-formulated chemotherapy) are already FDA-approved and in clinical use.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBe aware of the economic context.\u003c\/strong\u003e If nanomedicine becomes a standard treatment, cost and access could be significant issues, particularly in developing countries. Patient advocacy for equitable access to advanced therapies matters.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWatch for emerging trends.\u003c\/strong\u003e The research points to silver nanoparticles, gold nanoparticles, and green synthesis methods as the next wave of innovation. These environmentally friendly production methods may eventually make nanoparticle therapies more affordable and accessible.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFocus on the fundamentals.\u003c\/strong\u003e This research ultimately reinforces the importance of early detection and prevention. Landmark cancer statistics papers — the most co-cited references in the field — remind us that understanding cancer burden and risk factors is the foundation of reducing deaths from gynecologic cancers.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe most important message from this study is one of \u003cstrong\u003ehope grounded in evidence\u003c\/strong\u003e. Over the past two decades, researchers worldwide have built an impressive foundation of knowledge about how nanoparticles can be harnessed to fight gynecologic cancers. The field is mature enough to identify clear future directions, and the momentum of research — sustained at roughly 290 publications per year — suggests that nanoparticle-based approaches will play an increasingly important role in the future of cancer care.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat are nanoparticles and how might they help treat gynecologic cancers?\u003c\/h3\u003e\n\u003cp\u003eNanoparticles are ultra-small particles, far thinner than a human hair, engineered to carry drugs directly to tumors. They allow precise targeted delivery and controlled drug release, reducing damage to healthy organs and improving drug solubility. This could help overcome limitations of standard chemotherapy and other treatments.\u003c\/p\u003e\n\u003ch3\u003eAre nanoparticle-based treatments for gynecologic cancers available to patients now?\u003c\/h3\u003e\n\u003cp\u003eMost nanoparticle approaches are still in research and development. However, some formulations, such as liposomal doxorubicin, a nano-formulated chemotherapy, are already FDA-approved and in clinical use. Ask your oncologist whether you might be eligible for a trial involving nanoparticle drug delivery systems.\u003c\/p\u003e\n\u003ch3\u003eWhat does 'green synthesis' of nanoparticles mean and why is it important?\u003c\/h3\u003e\n\u003cp\u003eGreen synthesis refers to environmentally friendly methods for producing nanoparticles, such as silver and gold nanoparticles. The research suggests this is an emerging trend. These methods may eventually make nanoparticle therapies more affordable and accessible by reducing production costs and toxic byproducts.\u003c\/p\u003e\n\u003ch3\u003eWhat should I ask my doctor about nanoparticle-based cancer treatments?\u003c\/h3\u003e\n\u003cp\u003eAsk whether you might be eligible for clinical trials involving nanoparticle drug delivery systems. Also ask about current standard treatments and any FDA-approved nanomedicine options, like liposomal doxorubicin. Discuss potential costs and access issues, as these therapies may not be widely available yet.\u003c\/p\u003e\n\u003ch3\u003eWhat were the main limitations of this analysis?\u003c\/h3\u003e\n\u003cp\u003eThis was a bibliometric analysis of publications, not a test of nanoparticles in patients. It only included English-language articles from a single database. It cannot prove clinical effectiveness, and citation counts may reflect factors other than research quality, such as self-citation or the tendency to cite well-known authors.\u003c\/p\u003e\n\u003ch3\u003eWhat are the current standard treatments for gynecologic cancers?\u003c\/h3\u003e\n\u003cp\u003eSurgery, chemotherapy, radiotherapy, and immunotherapy remain the standard of care. Each has limitations, such as surgical risks, chemotherapy toxicity, or limited effectiveness in certain tumors. Nanoparticle approaches are largely in development, though some nano-formulated drugs are already approved and in clinical use.\u003c\/p\u003e\n\u003ch3\u003eMy gynecologic cancer was diagnosed and my oncologist recommended standard chemo or surgery. Should I seek a second opinion about nanoparticle-based treatments or clinical trials?\u003c\/h3\u003e\n\u003cp\u003eFor gynecologic cancers, standard care remains surgery, chemotherapy, radiotherapy, and immunotherapy. Nanoparticle-based approaches are mostly in research, though some formulations like liposomal doxorubicin are already FDA-approved. A second opinion can help clarify whether you might be eligible for a clinical trial using nanoparticle drug delivery, and whether an experimental option is advisable given your specific cancer type. It can also confirm that your recommended treatment plan aligns with the latest research on targeted delivery and reducing chemotherapy toxicity. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Nanoparticles in gynecologic cancers: a bibliometric and visualization analysis.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Zhou Y, Chen L, Wang T.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Frontiers in Oncology, Volume 14, Article 1465987\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication date:\u003c\/strong\u003e January 8, 2025\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.3389\/fonc.2024.1465987\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eStudy type:\u003c\/strong\u003e Systematic Review (Bibliometric and Visualization Analysis)\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It has been adapted to explain the study's findings in accessible language while preserving all key data and conclusions. The original article is published under a Creative Commons Attribution License (CC BY), allowing for distribution with appropriate credit.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47499367809180,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/products\/nanoparticles-in-gynecologic-cancers-a-20-year-research-review-made-simple","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}